SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC

Sponsor
Huazhong University of Science and Technology
Study ID
NCT05438108
Phase
PHASE2
Status
Unknown

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Immune checkpoint inhibitors have a poor effect on MSS colorectal cancer. Studies have shown that SBRT, chemotherapy and anti-vascular therapy can enhance the anti-tumor effect of PD-1 antibody. This is a prospective, single-arm study to explore the efficacy and safety of SBRT Sequential CapeOX Regimen Chemotherapy Combined With Bevacizumab and Sintilimab in treatment with patients with initially unresectable advanced colorectal cancer.

Key Dates

First listed
Jun 29, 2022
Start date
Jul 1, 2022
Status verified
Jun 2022
Primary completion
Jan 31, 2023
Completion
Jan 31, 2024

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SBRT sequential chemotherapy, bevacizumab and sitilimab

Primary Outcome Measure

Objective response rate (ORR) [ Time Frame: up to 12 months ]

Central Contacts

Related Studies